secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vistagen Therapeutics, Inc. (VTGN)
CIK:        0001411685
Form:       8-K
Filed at:   2025-02-13T23:59:59+00:00
Accession:  0001411685-25-000017
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vistagen reports Q3 FY2025 net loss $14.1M; fasedienol Phase 3 progressing
--------------------------------------------------------------------------

- Net loss $14.1M for Q3 ended Dec 31, 2024, vs $6.4M YoY; R&D expense rose to $11.3M from $4.5M.
- Cash and marketable securities $88.6M as of Dec 31, 2024.
- Fasedienol PALISADE-3 and PALISADE-4 Phase 3 trials for SAD ongoing; top-line results expected later 2025.
- Positive exploratory Phase 2A results for PH284 in cancer cachexia announced.
- IND-enabling program for PH80 for menopausal hot flashes continuing; Phase 2B planning for itruvone in MDD.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1411685/000141168525000017/0001411685-25-000017-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1411685/000141168525000017/vtgn-20250213.htm
  HTML page:      https://secwatch.observer/filing/0001411685-25-000017

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer